New Mesoblast Data Offers Hope for High-Risk Heart Patients

The latest updates from Mesoblast's Phase III trial on rexlemestrocel-L show that the drug provides the highest benefit when used in patients with certain types of chronic heart failure.

Data from the landmark DREAM-HF Phase III demonstrates that patients with chronic heart failure and low ejection fraction (HFrEF) and diabetes and/or myocardial ischemia benefit the most in major adverse cardiovascular events (MACE) in terms of a non-fatal heart attack or stroke, or cardiovascular death.